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The crystal structure of monoclonal antibody (mAb)
6B5 Fab fragment complexed with 1-(1-phenylcyclo-
hexyl)piperidine (PCP or phencyclidine) was deter-
mined at 2.2-Å resolution. 6B5 was originally produced
from a mouse immunized with a phencyclidine analogue
hapten 5-[N-(1*phenylcyclohexyl)amino]pentanoic acid
conjugated to bovine serum albumin. This mAb was se-
lected for further study because of its high affinity (Kd 5
2 3 10–9 M/liter) for PCP and usefulness in reversing
PCP-induced central nervous system toxicity in labora-
tory animals. The dominant feature of the 6B5 FabzPCP
complex is the deep binding site and hydrophobic na-
ture of the interaction. The ligand binding pocket of 6B5
Fab has numerous aromatic side chains, as compared
with other known Fab structures. The most notable fea-
ture of the binding site is a Trp at position 97H (H-
chain), and the side chain of this residue appears to act
as a hydrophobic umbrella on the ligand in the antigen
binding pocket. There are only two other known Fabs
found with a Trp at the 97H position in complementarity
determining region (CDR) H3, but they do not play a
major role in the interaction with their respective anti-
gens; in both Fab TE33 and R6.5 the Trp 97H side chain
is positioned away from the bound antigen. Comparison
of the CDR residues of 6B5 with other Fab structures
with similar CDR sizes and amino acid compositions
reveals a number of important patterns of residue sub-
stitutions that appear to be critical for specific PCP
ligand interactions.
Crystallographic determinations of antigen binding frag-
ments (Fab)1 derived from human and mouse immunoglobulins
(Ig) have shown that the antigen binding pocket is created by
six polypeptide loops or so-called complementarity determining
regions (CDR) at the en face region of the Fab (1–3). The CDR
structures are formed by the anti-parallel b-strand turns of the
variable regions of light and heavy polypeptide chains. The
favorable contacts between specific CDR amino acids of the
antibody and the antigen epitopes accounts for the fine speci-
ficity of the interaction. Although most antibodies made
against small ligand or drug antigens exhibit precise stereospe-
cific interactions, it is not uncommon for some antibodies to
bind to analogues or drug family members that are structurally
related due to the position and orientation of specific intermo-
lecular contacts.
Phencyclidine (1-(1-phenylcyclohexyl)piperidine, or PCP)
and related arylcyclohexylamines have been shown to be potent
dissociative psychotropic agents (4, 5). PCP has direct interac-
tions with receptors for several central nervous system neuro-
transmitters, including the N-methyl-D-aspartate gated ion-
channel complex (6) and the dopamine reuptake transporter (7,
8). The molecular features of PCP-like arylcyclohexylamines
which are important for binding to the PCP binding site have
been studied by generation of a series of polyclonal rabbit
antibodies and mouse monoclonal antibodies (mAbs) to PCP-
like haptens and related analogues (9, 10). By comparing the
relative reactivity of various arylcyclohexylamine drugs in a
[3H]PCP radioimmunoassay with their relative potencies for
PCP receptor binding in central nervous system membranes
and central nervous system drug discrimination assays in rats,
it was determined that 5-[N-(19phenylcyclohexyl)amino]pen-
tanoic acid (PCHAP) was a highly suitable ligand for generat-
ing antibodies that could recognize the pharmacologically ac-
tive features required for arylcyclohexylamine binding to the
PCP sites (9).
We report here the crystal structure of a FabzPCP complex
resolved at 2.2-Å resolution. The monoclonal antibody used in
this study, clone 6B5, was produced against the phencyclidine-
like hapten PCHAP (11). The structural knowledge of this
FabzPCP complex has aided our understanding of how this
mAb is able to reverse acute PCP-induced central nervous
system toxicity within minutes following intravenous adminis-
tration (12). PCP is a well known drug of abuse and treatment
of its overdose in humans is extremely problematic because
there are no known antagonists and there is an extensive
extravascular distribution and slow elimination of the drug in
humans (13). Fab fragments of mAb 6B5 have been shown to be
highly effective as an antibody-based treatment protocol for
acute PCP toxicity in laboratory animals (11, 12). The struc-
tural knowledge of the 6B5 FabzPCP complex will provide the
basis for future 6B5 Fab and single-chain Fv (fragment vari-
able) protein engineering experiments in an attempt to modify
the antigenicity and enhance the pharmacokinetics, thereby
providing a basis for clinical application of this antibody in the
treatment of human patients with PCP-induced psychosis and
toxicity.
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EXPERIMENTAL PROCEDURES
Crystallization and Data Collection—The 6B5 Fab was produced and
purified from whole IgG (G1, k) as described previously (11). It was
further purified in an affinity gel column conjugated with the PCHAP
hapten, from which the 6B5 Fab was eluted with 0.1 M glycine-HCl
buffer, pH 2.8. The affinity-purified Fab was concentrated and exam-
ined for purity with SDS-PAGE. At a concentration of 15 mg/ml, the
6B5 Fab was crystallized in 2.2 M ammonium sulfate and 0.1 M sodium
acetate, pH 4.6, by the hanging drop crystallization method. The dif-
fraction data were collected to 2.2-Å resolution with the MAC Science
DIP2030 image plate system with double-focusing mirrors coupled to a
Rigaku x-ray generator, using a copper rotating anode with a 5 mm
nickel filter and a 0.5-mm x-ray beam collimator. The Denzo and Scale-
pack programs were used to autoindex, integrate, and scale multiple
frames of data (14). Intensity data sets collected from two crystals gave
a residual Rmerge of 9.1% and were assigned the space group of P1.
Summary of data collection and refinement statistics are presented in
Table I.
Molecular Replacement and Structure Refinement—To obtain the
molecular replacement solution for the 6B5 FabzPCP complex, the
4–4-20 Fab (Protein Data Bank code 4fab) and HC19 Fab (Protein Data
Bank code 1gig) structures were used as models in the search with the
XPLOR program (15). These structures were chosen because of their
common constant G1, k chain sequences with 6B5. Using the 15.0–
4.0-Å data, rotation search was performed separately for the variable
and constant domain halves of the Fab. Because each variable or
constant domain half consists of light and heavy chain subdomains, the
Patterson correlation refinements were performed after the initial ro-
tation search to improve their relative orientations. Top solutions from
these refinements were used in the translation search. The size of the
crystal lattice (Table I) indicated that there are two Fabs in the asym-
metric unit with the solvent content of 45% (16). Because the space
group is triclinic P1, no translation was necessary for the first variable
domain pair, and three translation searches were performed for the
remaining three Fab domain pairs of the asymmetric unit. The partial
structure factors Fc for the first variable domain pair were computed
and used in the translation search for the corresponding constant
domain pair. Then a new set of Fc was computed for the translation
search for the second variable domain pair. Again, a new set of Fc was
computed and used in the translation search for the second constant
domain pair. The 4–4-20 Fab model was used to determine the posi-
tions of the first three domain pairs but did not yield a solution for the
second constant domain pair. The position of the latter was determined
with the HC19 Fab model. The correlation coefficient improved progres-
sively from 0.19 with only one variable domain pair positioned to 0.38
with all four components placed in the crystal lattice. The molecular
replacement search with the 15.0–4.0-Å data also lowered the R factor,
from 51.5 to 46.2%. Furthermore, the same solution was also obtained
with another program, AMORE (17). Finally, the four Fab domain pairs
were placed together in the crystal lattice and rigid body minimization
was performed with the 8.0–3.0-Å data, and the R factor was further
reduced to 44.7%.
For the structural refinements, omit maps computed from the 4,000
K-simulated annealing calculations with XPLOR were examined to
ascertain the polypeptide tracing, especially for the CDR loops. Non-
crystallographic restraints were not used on the two Fabs in the asym-
metric unit during any part of the structure refinements. Structure
visualization and model building tasks were performed with the O
program (18). The amino acid substitutions were made in the 6B5
structure using the variable domain sequences for both L- and H-chains
derived from the cDNA nucleotide sequencing of mRNA isolated from
hybridoma cells (19) (Fig. 1). The constant domain sequences of 6B5
were not determined by cDNA sequencing. Because the constant do-
main gene families were found to be the same as the anti-lysozyme
antibody HyHEL-5 (20), the HyHEL-5 structure was used for the elec-
tron density maps of the 6B5 diffraction data.
The position of the PCP molecule in the Fab binding site was deter-
mined with the Fo 2 Fc difference map. The initial difference map
indicated the presence of PCP at the center of the binding site. As the
CDR loops with their side chains were built into the Fab structure with
more certainty, the difference electron density of PCP became more
defined. However, because PCP consists of three cyclic substituents,
there was uncertainty about its true orientation in the binding site.
This question was answered when the simulated annealing computa-
tion was performed with all the highest resolution data available (to 2.2
Å) and the difference electron density map revealed the PCP orientation
(Fig. 2A). The published coordinates of the PCP crystal structure (21)
were inserted in the model and another round of simulated annealed
calculations were performed (Fig. 2B). The potential parameters for
PCP were obtained from an automatic XPLOR parameter-generating
program (available on the web site: http://alpha2.bmc.uu.S.E./hicup)
(22, 23).
Ordered water molecules in the 6B5 Fab structure refinements,
which used the 6.0–2.2-Å data, were chosen from the 3 s peaks in the
Fo 2 Fc difference map with appropriate distance and interaction cri-
teria, and symmetry consideration. After their inclusion in the model,
their positions were again examined with the 2Fo 2 Fc map; any water
molecules with less than 0.7 s peaks in this map were rejected. The
final R factor was 19.9%, with Rfree of 28.6%. The refinement statistics
are summarized in Table I. Coordinates of the 6B5 Fab structure have
been deposited in Brookhaven Protein Data Bank (identification code
2PCP).
RESULTS
Overall Structure—The three-dimensional structure of 6B5
Fab complexed with PCP was determined to 2.2-Å resolution.
6B5 Fab possesses the typical immunoglobulin fold found in all
antibody molecules, wherein the light (L) chain and heavy (H)
chain form the variable (V) domain that contains the antigen-
binding region, and constant (C) domain that have identical
amino acid sequences within a gene class. Two FabzPCP com-
plexes were identified in the asymmetric unit of space group
P1. They are positioned in opposite directions with the inter-
face at the constant domain (Fig. 3). Amino acids of 1L to 211L
of L-chain (216 residues) and of 1H to 226H of H-chain (215
residues) were assigned in both Fab of the asymmetric unit
(Fig. 1). Amino acid sequence numbering scheme for Ig as
described by Kabat et al. (24) is used in this report. Most of the
FIG. 1. Amino acid sequences of 6B5
Fab. The full sequences of 6B5 are shown
to indicate the conserved b-strands (in
boxes) of which Ca atoms were used in
structure analysis. Also indicated are the
amino acids of complementarity-deter-
mining regions (CDRs) at the antigen-
binding site. Sequence numbers are as-
signed as in Kabat et al. (24).
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structural elements are well defined and unambiguously as-
signed, including the PCP ligand. The two regions of relatively
weak electron densities are amino acid residues 198L-203L in
the constant L-chain domain and 127H-133H in the constant
H-chain domain.
The structure of 6B5 was analyzed using Ca atoms of con-
served b-strand residues, as indicated in Fig. 1 and shown in
Table II. The Ca atoms of variable or constant domain of the
heavy chain are rotated to superimpose on the corresponding
Ca atoms of the light chain. The axis of this rotation between
the two chains is termed pseudodyad. The elbow angle is com-
puted with the two pseudodyads of the variable and constant
domain pairs. The elbow angles are 143° for Fab 1, and 139° for
Fab 2. These values deviate significantly from 180° but fall
within the range of those of other Fabs surveyed, from 127 to
227° (25). Pseudodyads are more close to 180° for V domains
than for C domains (Table II). In addition, molecular surface
areas were computed with the probe radius of 1.7 Å (26). The
buried surface area of the VL-VH interface is 1,309 Å2 for Fab
1 (663 for VL and 646 for VH) and 1,299 Å2 for Fab 2 (664 for
VL and 635 for VH). These values of 6B5 are in the mid-range
of those observed in other Fab structures (1,100 to 1,700 Å2)
(27) and comparable with the buried surface area of 1,375 Å2
for the anti-fluorescein 4–4-20 Fab (28), the search model for
6B5. However, the elbow angle of 171° of 4–4-20 is much
greater than that of 6B5.
The elbow angles of 6B5 Fab reflect the uneven positions of
the V- and C-domains of L-chain relative to that found in the
H-chain. The distances between the centers of mass for the Ca
atoms of conserved b-strand residues (Fig. 1) are 39 Å for VL
and CL, and 32 Å for VH and CH. The differences of these
values between the two Fabs are within 1 Å. The elongation on
the L-chain side causes the 198L-203L loop of CL to be at least
16 Å away from the nearest VL residues, 12L-14L. The 198L-
203L loop is usually stabilized in part with the close association
with the VL residues. The orientation of the V- and C-domain
interface causes this loop to be exposed to the solvent, resulting
in electron densities that are relatively weaker than those of
the remainder of the Fab. The disorder of this loop is reflected
by the relatively large average temperature factors, 49.3 and
45.6 Å2 for Fab 1 and Fab 2, respectively. These values are
twice that of the mean temperature factors for FabzPCP 1, 21.5
Å2, and for FabzPCP 2, 22.8 Å2 (Table I). In contrast, the
compression on the H-chain portion of the molecule results in a
closer interaction between VH and CH, and as a result, the
212H-217H loop of CH comes within 8 Å of the nearest residues
of VH, 9H-11H.
The two Fabs in the asymmetric unit point in opposite direc-
tions and have their interfaces at the C-domains (Fig. 3). It
requires a near symmetric 179.4° rotation to superimpose one
Fab to the other. Because noncrystallographic symmetry re-
straints were not used during any stage of refinement, the
r.m.s. deviation of all Ca atoms is 1.33 Å. The r.m.s. deviation
is 0.97 Å when only the Ca atoms of conserved b-strand resi-
dues are used. The r.m.s. deviations of different domain super-
positions are shown in Table II. These values are less than 1 Å
when only the Ca atoms of conserved b-strand residues are
used, which indicate that the relative positions of the constant
and variable domains are different between the two Fabs and
result in different elbow angles. In addition, the larger r.m.s.
deviation in the constant domains is caused, in part, by the
198L-203L loop of CL (0.72 Å), as discussed above, and the
127H-133H loop in CH, for which the r.m.s. deviation is 1.78 Å.
This loop has been found to be disordered in other Fab struc-
tures (29). The 127H-133H loops from the two 6B5 Fab in the
asymmetric unit face each other. Although omit map calcula-
tions allowed these loops to be traced, their electron densities
are relatively weak, as indicated by high average temperature
factors, 37.9 Å2 for the Fab 1 loop and 47.3 Å2 for the Fab 2 loop.
PCP Interaction with Fab Residues—The refined structure of
PCP in the Fab binding site deviates little from the crystal
structure of pure PCP (21). The phenyl ring is in axial position
and the piperidine ring in equatorial position, with respect to
the cyclohexane ring, thus forming a “T” formation (Fig. 2). The
r.m.s. deviation is 0.168 Å for PCP in Fab 1 and 0.143 Å for PCP
in Fab 2 when each is compared with the crystal PCP structure.
The phenyl ring has rotated in opposite directions for the two
PCP molecules, by about 10° for PCP in the Fab 1 and 5° for
PCP in the Fab 2. The PCP in the binding site was refined with
the default potential parameters obtained from the XPLOR
parameter-generating program (22), which assigned 1,000
kcal/mol Å22 for bond length constants and 500 kcal/mol rad22
for bond length constants. Eighty percent reduction of these
constants resulted in r.m.s. deviation of greater than 0.3 Å and
showed significant distortions of the PCP cyclic substituents.
In contrast, increase of these parameters by 20 times resulted
in the r.m.s. deviation of 0.1 Å, though the phenyl ring rotation
was still evident to a smaller extent. Between these two ex-
tremes, the default parameters were judged to be reasonable
for usage in these structural refinements.
The binding pocket of 6B5 Fab is about 13 Å in diameter and
13 Å deep. The PCP ligand is surrounded on all sides by
aromatic and histidine residues (Fig. 4). At the bottom of the
binding pocket, Phe 100H and the adjacent Phe 89L contact the
cyclohexane ring of PCP. At the middle portion of PCP, the
surrounding residues are Tyr 32L, His 27dL, and Tyr 96L from
the L-chain and Trp 47H, His 35H, Tyr 50H, and Tyr 33H from
the H-chain. The phenyl ring of PCP points toward Tyr 33H
FIG. 2. Electron density map of PCP from 6B5 Fab binding site
at 2.2 Å resolution. A, Fo 2 Fc difference map of PCP contoured at 2.7
s which indicated the proper orientation of PCP in the binding site. B,
2Fo 2 Fc map contoured at 1.0 s after the inclusion of PCP in the
structure. Molecular structures are drawn with the Molscript program
(41).
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and Tyr 50H. The side chain of His 35H is perpendicularly
positioned below the phenyl ring of PCP. Positioned above, and
enclosing PCP in the binding site, is Trp 97H. Polar interac-
tions include the nitrogen atom of the PCP piperidine ring (pKa
8.5), which is in close contact with the carbonyl oxygen atom of
Gly 91L (2.9 Å) and carbonyl oxygen atom of Trp 97H (3.8 Å).
The amino acid residues that surround those interacting
with PCP provide a support framework. In CDR 1L the side
chains of His 27dL and Tyr 32L interact with the PCP antigen,
and are stabilized by forming hydrogen bonds with Asn 28L
positioned between them. Tyr 32L is additionally stabilized by
Asn 30L and Asp 98H. On the H-chain side, aromatic side
chains of CDR 1H and 2H residues contribute to the interaction
with PCP. The Tyr 33H residue, which is in contact with the
phenyl ring of PCP, is stacked on the backside with the ring of
Tyr 52H. The side chain of Trp 47H does not make a direct
FIG. 3. Two complexes of FabzPCP
crystal structure in asymmetric unit
of P1 space group. PCP is shown in
solid images in the binding site of each
Fab.
TABLE I
Data collection and refinement statistics for the 6B5 Fab-PCP structure
Data collection Refinement
Space group P1 Resolution range 6.0–2.2
a, b, c (Å) 53.4, 67.7, 68.0 Reflections (uFu . 2 s) 31,830
a, b, g (°) 62.1, 84.7, 83.2 Non-hydrogen, non-water atoms 6,702
Number of crystals 2 Ordered water molecules 679
Maximum resolution (Å) 2.2 Rcryst
b, Rfree
c 0.199, 0.286
Total observations 69,236 r.m.s. dev. bond length (Å) 0.015
(I . 1 s) r.m.s. dev. bond angle (°) 2.4
Unique observations 33,694 r.m.s. dev. dihedral angle (°) 27.6
(I . 1 s) r.m.s. dev. improper angle (°) 2.3
Completeness (%) 79.3 Ramachandran plot quality (%)d
Rmerge
a 0.091 Fab-PCP 1 83.2, 15.9, 0.5, 0.3
,I/sI. 9.8 Fab-PCP 2 84.1, 15.1, 0.5, 0.3
Last shell range 2.4–2.2 Mean temperature factor (Å2)
Completeness (%) 63.5 Fab-PCP 1 21.5 6 9.3
Rmerge 0.221 Fab-PCP 2 22.8 6 9.2
,I/sI. 3.7 Water 26.8 6 12.0
a Rmerge 5 Si(SjuIij 2 ,Ii.u)/Si,Ii.; Iij is the scaled intensity of the jth observation of each unique reflection i and ,Ii. is the mean value.
b Rcryst 5 ShkluuFou 2 uFcuu/Shkl uFou.
c Rfree obtained from 3,074 reflections.
d Ramachandran plot quality compiled with the PROCHECK program (40) indicating percentages of main chain torsion angles in most favored
regions, additional allowed regions, generously allowed regions, and disallowed regions, respectively.
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contact with PCP but is close to it and is positioned between
those that are, such as Tyr 96L, His 35H, and Tyr 50H.
Table III identifies the buried molecular surface areas of the
PCP ligand and surrounding Fab residues. Both L and H-chain
CDR 3 make significant contributions to the interaction with
the ligand, in that 29% of buried surface area comes from CDR
3L and 35% from CDR 3H. CDR 3H makes the largest amount
of contact with PCP, and Trp 97H is a significant contact
residue with its side chain acting as an umbrella shielding PCP
from the solvent. Buried surface area contributed by Trp 97H
alone is 15%, more than any from the 16 residues that are in
contact with PCP. Furthermore, molecular surface area of PCP
complexed to Fab 1 is 252 Å2 and that complexed to Fab 2 is 254
Å2, and both are buried 97% by the surrounding Fab residues.
From the 679 ordered water molecules modeled in the asym-
metric unit of the two 6B5 FabzPCP structures, one water
molecule was found in each binding site, buried between PCP
and CDR residues. This single ordered water molecule is lo-
cated on the side of cyclohexane and piperidine rings of PCP
and interacts with the side chain of Glu 34L (Fig. 4).
The sequences and conformations of the CDR, except CDR
3H, are similar to those of other Fab structures. CDR 2L is
shielded by CDR 1L and 3H from making a direct contact with
PCP. CDR 1L in other Fab structures ranges from 10 to 17
amino acid residues in length. The relatively long CDR 1L of
6B5 (16 residues, Fig. 1) is often found in Fabs that bind small
ligand molecules (30, 31).
DISCUSSION
PCP, also known as “Angel Dust,” has become a widespread
and dangerous drug of abuse (4). There are numerous reports of
PCP inducing violent and bizarre behaviors (32). PCP can
precipitate latent psychosis and a drug-induced dementia that
resembles schizophrenia. Because there are no known antago-
nists for PCP, the treatment of the clinical problems associated
with PCP overdose is very difficult. Treatment of a drug over-
dose is compounded by the fact that PCP has a widespread
extravascular distribution and a very slow elimination from the
body. Both polyclonal and monoclonal antibody (6B5) treat-
ments of PCP toxicity in laboratory animals have proved suc-
cessful (12). The use of Fab 6B5 as a PCP antagonist has
resulted in a rapid reversal of PCP-induced behavioral toxicity
in the rat within minutes following intravenous administra-
tion. Administration of purified Fab 6B5 to humans with PCP
overdose may provide an effective and efficient treatment pro-
tocol for chemical-induced central nervous system toxicity.
Knowledge of the 6B5-PCP complex as reported herein, can
provide a basis for further Fab or single-chain Fv engineering
to modify the pharmacokinetics and antigenicity of the protein.
The binding pocket of antibody 6B5 Fab has a concentrated
amount of amino acids with aromatic side chains in the binding
site as compared with other known Fabs in the Protein Data
Bank, Brookhaven National Laboratory (Table III). A distin-
guishing feature of 6B5 is the presence and role of Trp 97H.
Recent examination of the Protein Data Bank revealed only
two other Fab structures with Trp in this position of the CDR
3H, TE33 (code 1tet) and R6.5 (code 1rmf). The tryptophan
residue in these other Fab structures does not appear to play a
critical role in the interaction with the antigen, in that the side
chain of Trp 97H swings outward from the antigen binding site.
Furthermore, the contact of Phe 89L with the PCP antigen
indicates a very hydrophobic nature of the binding pocket of
6B5. The position 89L is next to Cys 88L in the core of VL and
composed of Gln or Ser in about 70% of Fab structures, whereas
Phe occurs only in about 5%. The Phe 89L residue is usually
shielded from direct contact with antigen by CDR 3H residues
(e.g. TE33), but in 6B5 it seems to play an integral part in the
formation of hydrophobic binding pocket for PCP.
Fluorescence and circular dichroism (CD) spectroscopy are
useful techniques to probe antibody structures and the geomet-
ric arrangements of antigen or ligand contacts with aromatic
residues (33–35). We examined native 6B5 and its ligand-
complexed form for changes in the intrinsic Trp or Tyr fluores-
cence and changes in the CD spectra and failed to detect any
ligand-induced Trp or Tyr quenching, or measurable changes
in chromophore absorbency in the near UV spectrum.2 In some
antibody-ligand complexes, distinct changes in both intrinsic
Trp fluorescence and CD can be observed upon ligand binding,
and these observations have been in agreement with the crys-
tal structures (36). However, there were no observable changes
in the intrinsic fluorescence and CD spectra of 6B5-ligand
complexes as expected because of the location and direct ligand
contact with Trp 97H. This suggests a high degree of solvent
exposure of this residue and its orientation with respect to the
ligand (i.e. an absence of any p-p ring stacking arrangement)
may account for the absence of ligand-induced changes in the
spectroscopic signature of this mAb. In contrast, in the anti-
fluorescein 4–4-20 antibody, an induced CD spectra from the
bound fluorescein ligand appears to be because of a direct
ligand contact with several aromatic amino acids in the binding
site (37). For the anti-guanidinium sweetener antibodies NC6.8
and NC10.14, changes in both intrinsic Trp fluorescence and
near-UV CD were easily identified as being contributed from
the Trp 33H (for NC6.8) or Trp 91L and Tyr 101H (for NC10.14)
side chains that undergo p-p contacts with the p-cyanophenyl
ring of the ligand (35).
The binding site architecture of the anti-cholera toxin pep-
tide Fab TE33 (code 1tet) is very similar to that of 6B5 Fab (29).
The CDRs of both Fabs have the same number of residues and
similar amino acid composition and conformations, except CDR
3H which is one residue shorter in TE33 (sequence: 93ARR-
SWYF-DVW103). It is also interesting to note that the elbow
angle for TE33 is 142°, which is very close to that of 6B5 (Table
II). Both Fabs share similar backbone conformations as the
superposition of Ca atoms of conserved b-residues of combined
VL-VH domain pair results in 0.58 Å r.m.s. deviation. The
TE33 Fab binds a 15-residue peptide (only 12 residues reported
in the 1tet structure). Its binding site is concentrated with
aromatic residues nearly equivalent to that of 6B5, with small
but significant changes. For example, Tyr 33H of 6B5 is re-
placed in TE33 by Gly, so that the side chain of Gln 5 of the
peptide is inserted between the two b-strands (CDR 2H) of Fab
H-chain (Fig. 5). In TE33 the NE1 atom of Trp 97H ring
2 S. Y. Tetin and D. S. Linthicum, unpublished observations.
TABLE II
Quaternary structural analysis of 6B5 Fab
Elbow angle
Fab 1 143° Fab 2 139°
Pseudodyad
Fab 1 V 176° Fab 2 V 177°
Fab 1 C 170° Fab 2 V 168°
Superposition between two Fabs using Ca atoms (in Å)




VL 1 VH 0.49 0.37
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provides a hydrogen-bond with carbonyl oxygen atom of Ile 7 of
the peptide, as the C terminus of the peptide antigen point
away from the TE33 Fab binding site. An interesting feature of
this Fab is the placement of Arg 95H that forms a salt bridge
with Glu 34L. This is in contrast with 6B5, in which the long
side chain of Arg 95H is replaced by Ser, so that the PCP ligand
can be positioned in the corresponding space occupied by the
Arg 95H side chain in TE33, as shown in Fig. 5. In 6B5, Glu
34L interacts with Asp 99H on the opposite side of CDR 3H loop
from residue 95H. Thus, based on a framework of aromatic
residues that remains essentially unchanged, the replacement
of a few key residues in the binding site can alter the geometry
of ligand contacts, thereby resulting in an antibody with com-
pletely different antigen specificity.
Another Fab with the same CDR lengths as TE33, but dif-
ferent amino acid composition, is Jel-103, which binds RNA
(Protein Data Bank code 1mrd) (38). In Jel-103, the RNA an-
tigen is not placed deep in the binding pocket, which is mainly
because of the Arg 96L that is positioned below the RNA
antigen, and the RNA ring is stacked with Tyr 32L. In 6B5, Tyr
32L is in contact with the piperidine ring of PCP, and Tyr 96L
is positioned to the side of PCP. Thus, the PCP antigen is
allowed to be positioned deeper in the binding pocket. The Trp
97H residue in 6B5 is occupied by Arg in Jel-103, and its side
chain is arched toward the RNA to permit direct contacts with
the antigen. The Arg residues in these structures play very
different roles in the binding site.
The hapten used for generating the anti-PCP mAb 6B5 (i.e.
PCHAP) was chosen based on previous polyclonal antibody
ligand specificity studies (9). For these studies, anti-PCP rabbit
polyclonal antibodies were generated using a series of five
PCP-like haptens conjugated to protein carrier. Only the PC-
HAP hapten generated antibodies with a ligand reactivity pro-
file that mimicked the known pharmacological activity profile
FIG. 4. Stereo drawing of PCP in the 6B5 Fab binding site surrounded by aromatic amino acid side chains. Also shown are the
carbonyl oxygen atom of Gly 91L interacting with the lone nitrogen atom of PCP and a water molecule located adjacent to PCP in the binding
pocket.
TABLE III
Buried molecular surface areas for 6B5 Fab interaction with PCP
Fab 1 Fab 2
Residue Area (Å2) % Area Total CDR % area Residue Area (Å2) % Area Total CDR % area
His-27dL 18 6.1 His-27dL 12 4.5
Tyr-32L 22 7.8 Tyr-32L 18 6.8
Glu-34L 4 1.4 CDR 1L 15.3 Glu-34L 4 1.4 CDR 1L 12.7
Phe-89L 12 4.2 Phe-89L 16 6.0
Gly-91L 33 11.4 Gly-91L 21 8.1
Thr-92L 8 2.8 Thr-92L 5 2.0
Tyr-96L 31 10.5 CDR 3L 28.9 Tyr-96L 33 12.7 CDR 3L 28.8
Tyr-33H 17 5.8 Tyr-33H 18 6.7
His-35H 25 8.7 CDR 1H 14.5 His-35H 22 8.2 CDR 1H 14.9
Tyr-50H 17 5.9 CDR 2H 5.9 Tyr-50H 16 6.2 CDR 2H 6.2
Ser-95H 14 4.8 Ser-95H 13 4.9
Thr-96H 5 1.8 Thr-96H 7 2.6
Trp-97H 45 15.5 Trp-97H 40 15.0
Asp-98H 16 5.6 Asp-98H 12 4.6
Asp-99H 9 3.2 Asp-99H 14 5.4
Phe-100H 13 4.5 CDR 3H 35.4 Phe-100H 13 4.9 CDR 3H 37.4
Total 289 Total 264
PCP 1 245 97.2 PCP 2 247 97.2
Fab 6B5 Complexed with PCP 28581
of the central nervous system PCP receptor (i.e. the N-methyl-
D-aspartate ion-gated channel). Antibody 6B5 has a ligand
binding profile for arylcyclohexylamines that correlates with
pharmacological activity (10).
A comparison of the structural features of the PCP binding
site of 6B5 with that of the N-methyl-D-aspartate ion-gated
channel could prove useful. The molecular determinants of the
PCP binding site in the M2 segment of the oligomeric channel
has been examined by site-directed mutagenesis using the glu-
tamate receptor GluR1 (39). The PCP binding site is located in
a hydrophobic transmembrane segment of the M2 chain, and
binding of PCP acts to keep the channel open. Three specific
point mutations in the M2 region appear to confer PCP binding
specificity. Residues such as Trp-577 and Trp-593 appear to be
essential to PCP binding, but residues such as Thr-582 and
Ala-610 also appear to play critical roles. Thus, the geometry of
residues Trp-577, Trp-593, Thr-582, and Ala-610 in the ion-
gated channel site may be similar to those in 6B5, especially
with respect to ligand contacts and binding specificity for re-
lated psychoactive arylcyclohexylamines.
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FIG. 5. Comparison of PCP binding to 6B5 Fab and cholera toxin peptide binding to TE33 Fab (29). The two structures are
superpositioned to indicate that the two Fab binding sites with a similar framework can accommodate the different types of antigen molecules by
replacements of amino acid substitutions at key positions. For the larger cholera toxin peptide to bind, Tyr 33H of 6B5 is changed to Gly in TE33.
Also, the Trp 97H side chain is positioned above the PCP antigen in 6B5; however, this side chain ring is turned away from the center of the binding
site to allow for the positioning of the peptide antigen in TE33. In addition, Arg 95H in TE33 is changed to serine in 6B5 so that the PCP antigen
is allowed to be inserted deeper into the binding site.
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